Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel

STAGER, G. G., J. ABRAHÁMOVÁ, F. BACANU, S. BRINCAT, A. BRIZE, A. CESAS, T. CUFER, M. DANK, R. DUCHNOWSKA, A. ENIU, J. JASSEM, Z. KAHAN, E. MATOS, P. PADRIK, S. PLATE, H. POKKER, G. PURKALNE, C. TIMCHEVA, V. TZEKOVA, Rostislav VYZULA and CH.C. ZIELINSKI. Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wiener Klinische Wochenschrift. Wien: Springer, 2010, vol. 122, 11-12, p. 368-379. ISSN 0043-5325. Available from: https://dx.doi.org/10.1007/s00508-010-1373-6.

Basic information

• Original name: Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel
• Authors: STAGER, G. G. (40 Austria, guarantor), J. ABRAHÁMOVÁ (203 Czech Republic), F. BACANU (642 Romania), S. BRINCAT (470 Malta), A. BRIZE (428 Latvia), A. CESAS (440 Lithuania), T. CUFER (705 Slovenia), M. DANK (348 Hungary), R. DUCHNOWSKA (616 Poland), A. ENIU (642 Romania), J. JASSEM (616 Poland), Z. KAHAN (348 Hungary), E. MATOS (705 Slovenia), P. PADRIK (233 Estonia), S. PLATE (233 Estonia), H. POKKER (233 Estonia), G. PURKALNE (428 Latvia), C. TIMCHEVA (428 Latvia), V. TZEKOVA (100 Bulgaria), Rostislav VYZULA (203 Czech Republic, belonging to the institution) and CH.C. ZIELINSKI (40 Austria).
• Edition: Wiener Klinische Wochenschrift, Wien, Springer, 2010, 0043-5325.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: Austria
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 0.747
• RIV identification code: RIV/00216224:14110/10:00051832
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.1007/s00508-010-1373-6
• UT WoS: 000279568000011
• Keywords in English: TYROSINE KINASE INHIBITOR; TRASTUZUMAB TREATMENT OPTIMIZATION; PHASE-II TRIAL; TARGETED THERAPIES; 1ST-LINE TREATMENT; CLINICAL-TRIALS; POOLED ANALYSIS; RECEPTOR; GROWTH; CELLS
• Tags: International impact

Abstract

In breast cancer, early detection as well as new developments in therapeutic options has resulted in less patients presenting with metastatic disease. However, about one-third of women with early stage breast cancer will eventually develop metastatic disease. Furthermore, approximately 20-30% of patients with breast cancer have tumors that overexpress human epidermal growth factor receptor (HER-2), which is associated with an aggressive tumor phenotype and poor prognosis. The identification of the HER-2 protein led to the development of highly effective therapeutics directed at this receptor. Trastuzumab, a recombinant, humanized, monoclonal antibody that binds to the extracellular domain of the HER-2 protein, has shown significant clinical benefit in metastatic and early-stage HER-2-positive breast cancer. Since the cancer recurs after adjuvant therapy in some women, and metastatic breast cancer eventually develops resistance to trastuzumab, there is a need for alternative treatment modalities to block HER-2 signaling. One of these treatment options is lapatinib, an orally active small molecule that inhibits the tyrosine kinases of HER-2 and the epidermal growth factor receptor type 1 (EGFR). In this consensus statement current treatment options in metastatic and locally advanced disease are discussed with a special focus on lapatinib.